President Trump Oct. 25 rolled out a three-pronged plan that would test ways to lower costs for some Medicare drugs directly administered by doctors. The plan has received criticism from all sides with Republicans and the drug industry comparing it to government price controls and socialized medicine, while Democrats are critical that it does not go far enough.
The demonstration project, which likely would not start until 2020 given the government’s rule making process, would impact just half of the country, although it is not known where. The Department of Health & Human Services will use an Obamacare program known as the Center for Medicare & Medicaid Innovation to run the plan.
